Trials that use: Risk difference
New to this method? Read the tutorial →
6,276 results
- PATENT-1Independent statistical analysis of PATENT-1, a randomized phase 3 trial of oral riociguat in patients with pulmonary arterial hypertension, covering its 6-minute walking distance endpoint, ANCOVA, nonparametric and stratified analyses, secondary outcomes,…
- PATHIndependent statistical analysis of PATH Partnering to Achieve Tobacco-free Health: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01533974).
- Patient Convenience Study (RE-SONANCE): Complete Statistical AnalysisIndependent statistical analysis of Patient Convenience Study (RE-SONANCE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02684981).
- Patient Preference Comparison of AZARGA Versus COSOPT: Complete Statistical AnalysisIndependent statistical analysis of Patient Preference Comparison of AZARGA Versus COSOPT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01340014).
- Patient Reported Satisfaction With Contoura LASIK Utilizing the Phorcides Analytic Software: Complete Statistical AnalysisIndependent statistical analysis of Patient Reported Satisfaction With Contoura LASIK Utilizing the Phorcides Analytic Software: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- PATTErnIndependent statistical analysis of A Study of Physical Activity paTTerns and Major Health Events in Older People With Implantable Cardiac Devices: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00625846).
- Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: Complete Statistical AnalysisIndependent statistical analysis of PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: Complete Statistical AnalysisIndependent statistical analysis of PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection: Complete Statistical AnalysisIndependent statistical analysis of PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03239899).
- PD0332991Independent statistical analysis of A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PDA+Independent statistical analysis of PDA+: A Personal Digital Assistant for Obesity Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00371462).
- PDC-1421 Treatment in Adult Patients With ADHD: Complete Statistical AnalysisIndependent statistical analysis of PDC-1421 Treatment in Adult Patients With ADHD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05202327).
- PDT/PDLIndependent statistical analysis of Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PEACE IIIndependent statistical analysis of Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: Complete Statistical AnalysisIndependent statistical analysis of PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors: primary endpoint…
- PEARL-IIndependent statistical analysis of A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection: primary endpoint results,…
- PEARL-IVIndependent statistical analysis of A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pecto-Intercostal Fascial Plane Block Study: Complete Statistical AnalysisIndependent statistical analysis of Pecto-Intercostal Fascial Plane Block Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04928339).
- PEDALIndependent statistical analysis of Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP): primary endpoint results, effect estimate with confidence…
- Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto): Complete Statistical AnalysisIndependent statistical analysis of Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02918773).
- Pediatric Head Lice Study Product Comparison: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Head Lice Study Product Comparison: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02213055).
- Pediatric Tonsillectomy Pain Reduction Study: Complete Statistical AnalysisIndependent statistical analysis of Pediatric Tonsillectomy Pain Reduction Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00678379).
- Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: Complete Statistical AnalysisIndependent statistical analysis of Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00944073).
- Peer Support Dyads in Churches: Complete Statistical AnalysisIndependent statistical analysis of Peer Support Dyads in Churches: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03463941).
- Peer to Peer Delivery of Behavioral Activation: Complete Statistical AnalysisIndependent statistical analysis of Peer to Peer Delivery of Behavioral Activation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02292849).
- PeerPrEPIndependent statistical analysis of Peer PrEP Referral + HIV Self-test Delivery for PrEP Initiation in Kenya: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- PEFCATIIIndependent statistical analysis of PEFCATII Expanded Safety and Feasibility Study of the FARAPULSE Endocardial Multi Ablation System to Treat Paroxysmal Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- PEGHOPEIndependent statistical analysis of An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy: primary…
- Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy: Complete Statistical AnalysisIndependent statistical analysis of Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PEGRescueIndependent statistical analysis of Prospective Evaluation of NOTES (Natural Orifice Translumenal Endoscopic Surgery) PEG "Rescue": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01758588).
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer: primary endpoint results, effect estimate…
- Pembro/Carbo/Taxol in Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembro/Carbo/Taxol in Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02549209).
- Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02658019).
- Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) in Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02940496).
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery: primary…
- Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02688608).
- Pembrolizumab in Combination With CRT for LA-SCCHN: Complete Statistical AnalysisIndependent statistical analysis of Pembrolizumab in Combination With CRT for LA-SCCHN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02586207).